Publication | Closed Access
Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics
412
Citations
25
References
2005
Year
Tumor XenograftsTargeted DeliveryPeptide EngineeringPeptide TherapeuticsDermatologyPhage DisplayTumor BiologyRadiation OncologyCell SignalingTumor TargetingNon-peptide LigandPharmacologyNovel Peptide LigandCell BiologyTumor MicroenvironmentBiomolecular EngineeringDrug TargetingSignal TransductionPolymer-drug ConjugatePeptide LibraryPeptide TherapeuticDrug Delivery SystemsMedicineDrug DiscoveryExtracellular Matrix
Epidermal growth factor receptor (ErbB1, EGFR) is overexpressed in a variety of human cancer cells. It has been considered as a rational target for drug delivery. To identify novel ligands with specific binding capabilities to EGFR, we screened a phage display peptide library and found an enriched phage clone encoding the amino acid sequence YHWYGYTPQNVI (designated as GE11). Competitive binding assay and Scatchard analysis revealed that GE11 peptide bound specifically and efficiently to EGFR with a dissociation constant of approximately 22 nM, but with much lower mitogenic activity than with EGF. We showed that the peptides were internalized preferentially into EGFR highly expressing cells, and they accumulated in EGFR overexpressing tumor xenografts after i.v. delivery in vivo. In gene delivery studies, GE11-conjugated polyethylenimine (PEI) vectors were less mitogenic, but still quite efficient at transfecting genes into EGFR highly expressing cells and tumor xenografts. Taken together, GE11 is a potentially safe and efficient targeting moiety for selective drug delivery systems mediated through EGFR.
| Year | Citations | |
|---|---|---|
Page 1
Page 1